Tovecimig Plus Paclitaxel Shows Breakthrough Progression-Free Survival Benefit in Advanced Biliary Tract Cancer

Clinical Trails /

The COMPANION-002 trial tested Tovecimig (CTX-009) combined with paclitaxel in patients with advanced biliary tract cancer who had already received prior treatment. The combination worked better than paclitaxel alone, nearly doubling progression-free survival to 4.7 months compared with 2.6 months. Tumor response rates were also higher, with 17.1% of patients responding versus 5.3% in the […]

Tovecimig Plus Paclitaxel Shows Breakthrough Progression-Free Survival Benefit in Advanced Biliary Tract Cancer Read More »

Personalized Advances Transform HR+ Breast Cancer Treatment with Early Intervention and Long-Term Benefits

Treatment /

Long-term data and molecular monitoring are reshaping treatment for hormone receptor–positive breast cancer, with a stronger focus on personalized and proactive care. Results from the NATALEE trial show that adding ribociclib to endocrine therapy reduces recurrence in early-stage disease. At four years, invasive disease-free survival was 88.5% with ribociclib versus 83.6% without, and the benefit

Personalized Advances Transform HR+ Breast Cancer Treatment with Early Intervention and Long-Term Benefits Read More »

FDA Approves New Cancer and Blood Disorder Treatments, Including Kidney, Leukemia, and Colorectal Screening Advances

Drug Approvals /

In early 2016, the FDA approved several important new cancer and hematology treatments. cabozantinib (Cabometyx) was approved for advanced kidney cancer after prior therapy. In trials, it nearly doubled the time patients lived without disease progression compared to everolimus (7.4 vs. 3.8 months) and showed a median overall survival of 21.4 months. Common side effects

FDA Approves New Cancer and Blood Disorder Treatments, Including Kidney, Leukemia, and Colorectal Screening Advances Read More »

Tebentafusp Doubles 5-Year Survival in Metastatic Uveal Melanoma, Long-Term Trial Shows

Treatment /

Five-year results show that tebentafusp (Kimmtrak) significantly improves long-term survival in patients with HLA-A*02:01–positive metastatic uveal melanoma. Historically, fewer than 10% of these patients survive five years, but tebentafusp increased the rate to 16%, compared to 8% with standard treatments such as pembrolizumab. Median overall survival also improved to 21.6 months versus 16.9 months, with

Tebentafusp Doubles 5-Year Survival in Metastatic Uveal Melanoma, Long-Term Trial Shows Read More »

Donor Fecal Microbiota Transplantation Boosts Immunotherapy Outcomes in Metastatic Kidney Cancer

Immunotherapy /

A phase 2a TACITO trial suggests that Fecal Microbiota Transplantation (FMT) from treatment responders may improve outcomes in metastatic renal cell carcinoma. Patients received standard immunotherapy with pembrolizumab and axitinib, along with either donor FMT or a placebo. Results showed clear benefits for the donor FMT group. Median progression-free survival was 24 months versus 9

Donor Fecal Microbiota Transplantation Boosts Immunotherapy Outcomes in Metastatic Kidney Cancer Read More »

Two-Step Strategy Targets TP53 gene Mutations, Offering Safer Cancer Treatment Approach

Research Advances /

Researchers have developed a new two-step treatment strategy that targets mutations in the TP53 gene, a defect present in more than half of all cancers. Unlike older approaches that often cause significant toxicity, this method is designed to specifically attack cancer cells while leaving healthy cells largely unharmed. The treatment works in two stages. First,

Two-Step Strategy Targets TP53 gene Mutations, Offering Safer Cancer Treatment Approach Read More »

LYT-200 Shows Promising Response Rates in High-Risk Myeloid Cancers

Treatment /

A new Phase 1b trial shows promising results for LYT-200, a first-in-class monoclonal antibody targeting galectin-9 in high-risk blood cancers. The drug is being tested in patients with relapsed or refractory myeloid malignancies who have already failed multiple treatments. In high-risk myelodysplastic syndrome, LYT-200 combined with standard therapy achieved a 45.5% overall response rate, with

LYT-200 Shows Promising Response Rates in High-Risk Myeloid Cancers Read More »

Daraxonrasib Shows Strong Early Results in First-Line Pancreatic Cancer Trials

Clinical Trails /

New early-stage trial results suggest that daraxonrasib (RMC-6236), a new targeted drug, may improve outcomes for patients with metastatic pancreatic cancer who have not yet received treatment. In two Phase 1/2 studies, daraxonrasib showed strong anti-tumor activity both alone and when combined with chemotherapy. Response rates reached 47% with the drug alone and 58% when

Daraxonrasib Shows Strong Early Results in First-Line Pancreatic Cancer Trials Read More »

GLP-1 Drugs Show Promise in Reducing Colorectal Cancer Risk

Research Advances /

GLP-1 receptor agonists, commonly used for diabetes and weight loss, may help reduce the risk of colorectal cancer. Drugs like semaglutide and tirzepatide showed promising results in a 2026 study, appearing more effective and safer than aspirin for prevention. People taking these drugs were 36% less likely to develop colorectal cancer, with risk reduced by

GLP-1 Drugs Show Promise in Reducing Colorectal Cancer Risk Read More »

Australia Approves Tafasitamab Triple Therapy for Relapsed Follicular Lymphoma

Drug Approvals /

Australia’s Therapeutic Goods Administration has approved a new three-drug combination—tafasitamab (Minjuvi) with rituximab and lenalidomide—for adults with relapsed or refractory follicular lymphoma, following a similar decision by the U.S. Food and Drug Administration in 2025. The approval is based on a Phase 3 trial showing the combination significantly improved outcomes. Patients receiving the triplet therapy

Australia Approves Tafasitamab Triple Therapy for Relapsed Follicular Lymphoma Read More »